Market Cap : 1 B | Enterprise Value : 933.74 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Myovant Sciences's Enterprise Value is $933.7 Mil. Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-187.0 Mil. Therefore, Myovant Sciences's EV-to-EBIT ratio for today is -4.99.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Myovant Sciences's Enterprise Value is $933.7 Mil. Myovant Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-183.9 Mil. Therefore, Myovant Sciences's EV-to-EBITDA ratio for today is -5.08.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Myovant Sciences's Enterprise Value is $933.7 Mil. Myovant Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $231.0 Mil. Therefore, Myovant Sciences's EV-to-Revenue ratio for today is 4.04.
The historical data trend for Myovant Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Myovant Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Myovant Sciences's Enterprise Value for the fiscal year that ended in Mar. 2022 is calculated as
Enterprise Value (A: Mar. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1263.51522 | + | 0 | + | 365.741 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.148 | + | 0 | - | 434.187 |
= | 1,197.2 |
Myovant Sciences's Enterprise Value for the quarter that ended in Mar. 2022 is calculated as
Enterprise Value (Q: Mar. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1263.51522 | + | 0 | + | 365.741 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.148 | + | 0 | - | 434.187 |
= | 1,197.2 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Myovant Sciences's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 933.735 | / | -186.962 | |
= | -4.99 |
Myovant Sciences's current Enterprise Value is $933.7 Mil.
Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-187.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Myovant Sciences's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 933.735 | / | -183.89 | |
= | -5.08 |
Myovant Sciences's current Enterprise Value is $933.7 Mil.
Myovant Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-183.9 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Myovant Sciences's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 933.735 | / | 230.972 | |
= | 4.04 |
Myovant Sciences's current Enterprise Value is $933.7 Mil.
Myovant Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $231.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Myovant Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
From GuruFocus
Other Sources
By Zacks 2021-10-29
By Seekingalpha 2021-10-26
By Zacks 2021-05-11
By Zacks 2021-05-27
By Zacks 2021-04-13
By Fool 2021-07-28
By Zacks 2021-07-28
By Zacks 2021-03-25
By Zacks 2021-02-11
By Seekingalpha 2020-12-22
By Zacks 2020-12-16
By Zacks 2021-10-26
By Zacks 2021-09-10
By Zacks 2020-12-29